Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases

Unexpected severe exacerbation or manifestation of primary disease related to nivolumab was noted in non-small-cell lung cancer (NSCLC) patients with a poor performance status or central nervous system metastases. Thus, we should monitor these patients when they are administered nivolumab.